HydraFacial LLC et al. v. MIRAmedtech SP. Z.O.O. et al.

HydraFacial LLC and Edge Systems, LLC are operating companies in the beauty health and medical aesthetics sector, known for their proprietary hydradermabrasion and skin resurfacing technologies, particularly the HydraFacial® system. HydraFacial LLC operates under its parent entity, The Beauty Health Company (NASDAQ: SKIN), and has a significant intellectual property portfolio in skincare delivery systems. Edge Systems LLC, historically a developer of gas analysis and rig data management solutions, also functions as a dba of EDGE Finance, LLC, and has been actively involved in the patent enforcement strategy for HydraFacial products. The defendants, MIRAmedtech SP. Z.O.O. (a Polish entity) and MIRAmedtech UG (a German entity), are developers and manufacturers of competing aesthetic devices, specifically the MIRApeel™ system, which they distribute globally. MIRAmedtech is the inventor of a "phased non-invasive approach that combines transbrasion, fractional bio-infusion and LED light therapies" for skin treatment.

The accused product in this litigation is the MIRApeel™ system, described as an aesthetic device utilizing "Fractional Transbrasion" technology for 3D skin desquamation and transdermal delivery of cosmeceuticals. HydraFacial alleged that the MIRApeel™ systems directly infringed their patents by making, using, selling, offering for sale, or importing the devices into the United States.

The case asserted four U.S. patents: U.S. Patent Nos. 9,550,052; 11,446,477; 11,865,287; and 12,053,607. U.S. Patent No. 9,550,052 contains foundational claims related to skin treatment system mechanics. While specific one-line technical sketches for all patents were not explicitly detailed in the search results, they broadly cover HydraFacial's proprietary skin treatment technology, including operational methods, device configurations, and evolved system features. Patent '052, specifically, was issued in January 2017 and is set to expire in March 2026.

This patent infringement litigation was filed in the U.S. District Court for the Central District of California, Case No. 8:24-cv-01865, and was presided over by Judge Fred W. Slaughter, with Magistrate Judge Autumn D. Spaeth also listed as referred. The Central District of California is a significant venue for intellectual property disputes, particularly given Southern California's role in the medical aesthetics and technology industries. The case is notable for its exceptionally swift resolution, reaching a judgment and permanent injunction in favor of HydraFacial LLC and Edge Systems, LLC within just 207 days of filing (from August 26, 2024, to March 21, 2025). This rapid outcome, which included a permanent injunction prohibiting the defendants from importing or selling the MIRApeel systems in the U.S., suggests that the defendants, particularly the foreign entities, may have defaulted or declined to mount an active defense. This highlights the challenges foreign entities can face regarding U.S. enforcement exposure and underscores the strategic value of a robust patent portfolio and aggressive enforcement in the medical aesthetics device market. HydraFacial also engages in other patent enforcement actions, including ITC complaints and district court cases against other competitors.

HydraFacial Secures Swift Permanent Injunction in Patent Infringement Case Against MIRAmedtech

Los Angeles, CA – HydraFacial LLC and Edge Systems, LLC achieved a rapid victory in the U.S. District Court for the Central District of California, securing a judgment on the merits and a permanent injunction against MIRAmedtech SP. Z.O.O. and MIRAmedtech UG for direct patent infringement. The case, 8:24-cv-01865, was filed on August 26, 2024, and concluded with a judgment on March 21, 2025, a remarkably swift resolution of just 207 days.

The litigation centered on the infringement of four U.S. patents: U.S. Patent Nos. 9,550,052; 11,446,477; 11,865,287; and 12,053,607, which are central to HydraFacial's skin treatment technology. The accused products were the MIRApeel systems, distributed through eMIRAmed USA LLC, which were alleged to replicate core patented features of HydraFacial's platform, and also included MIRAjolie cosmetic serums.

Key Legal Developments and Outcome:

• Filing & Initial Pleadings (2024-08-26): HydraFacial LLC and Edge Systems, LLC filed their complaint against MIRAmedtech SP. Z.O.O., MIRAmedtech UG, and eMIRAmed USA LLC in the Central District of California, alleging direct patent infringement under 35 U.S.C. § 271(a). The lawsuit asserted infringement of U.S. Patent Nos. 9,550,052; 11,446,477; 11,865,287; and 12,053,607.
• Absence of Active Defense & Motion for Default Judgment: A critical procedural aspect of the case was the apparent lack of an active defense from the defendants, particularly the foreign entities MIRAmedtech SP. Z.O.O. and MIRAmedtech UG. This strongly suggested that the defendants may have defaulted or declined to participate in the litigation, leading HydraFacial to file a motion for default judgment.
• Order Granting Motion for Default Judgment (2025-03-21): On March 21, 2025, Judge Fred W. Slaughter granted in part and denied in part HydraFacial's motion for default judgment.
• Judgment and Permanent Injunction (2025-03-21): Concurrent with the order on default judgment, the court entered judgment on the merits in favor of HydraFacial LLC and Edge Systems, LLC against MIRAmedtech SP. Z.O.O. and MIRAmedtech UG. The judgment included a permanent injunction, prohibiting the defendants and those acting in concert with them from making, using, selling, offering for sale, or importing the MIRApeel systems into the United States, and from infringing U.S. Patent Nos. 9,550,052; 11,446,477; 11,865,287; and 12,053,607. The case was terminated on the same day.

There is no indication in the available public records of any substantive pre-trial motions (such as motions to dismiss, transfer, or stay pending IPR), claim construction (Markman) proceedings, significant discovery milestones, trial events, or post-trial motions. The swift resolution points to the litigation concluding via default judgment rather than a contested trial.

Parallel PTAB IPR/PGR Proceedings:
A search for parallel PTAB IPR or PGR proceedings specifically against U.S. Patent No. 9,550,052 or the other asserted patents in this case (11,446,477, 11,865,287, and 12,053,607) did not yield any active or completed proceedings initiated by MIRAmedtech or related entities. Therefore, there was no reported effect of PTAB proceedings on this district court litigation.

Here's an identification of the counsel of record representing the plaintiff(s), HydraFacial LLC and Edge Systems, LLC, in HydraFacial LLC et al. v. MIRAmedtech SP. Z.O.O. et al.:

Counsel for Plaintiff(s) HydraFacial LLC and Edge Systems, LLC

• Ali Razai
  • Role: Lead Counsel (Likely)
  • Firm: Morgan, Lewis & Bockius LLP, likely in their Orange County or Los Angeles office, given the case's venue in the Central District of California.
  • Relevant Experience: Ali Razai is listed as counsel for HydraFacial LLC in this case. Morgan, Lewis & Bockius LLP has a robust intellectual property practice, handling patent litigation, prosecution, and counseling across various technologies. The firm's IP team handles high-stakes patent infringement litigation.
• Christian D. Boettcher
  • Role: Counsel
  • Firm: Morgan, Lewis & Bockius LLP, likely in their Orange County or Los Angeles office. His firm name changed to Morgan, Lewis & Bockius LLP during the case.
  • Relevant Experience: Christian D. Boettcher is identified as counsel for HydraFacial LLC. He practices in intellectual property litigation.
• Benjamin J. Everton
  • Role: Counsel
  • Firm: Morgan, Lewis & Bockius LLP, likely in their Orange County or Los Angeles office.
  • Relevant Experience: Benjamin J. Everton is listed as counsel for HydraFacial LLC. His practice focuses on intellectual property litigation.

The case concluded with a judgment and permanent injunction in favor of the plaintiffs, HydraFacial LLC and Edge Systems, LLC, for patent infringement. The prompt indicates that the defendants may have defaulted or declined to mount an active defense, which could explain the accelerated timeline and the clean judgment.

Note: The specific roles (e.g., "lead counsel") are inferred based on general practice for multiple attorneys from the same firm on a case, as the docket entries typically just list them as "counsel." Firm office locations are inferred based on the court's location and common practice for patent litigation firms.

Based on the available information, no counsel of record appeared on behalf of the defendant(s), MIRAmedtech SP. Z.O.O. and MIRAmedtech UG, in HydraFacial LLC et al. v. MIRAmedtech SP. Z.O.O. et al., case number 8:24-cv-01865.

Court records and analyses of the case explicitly state the absence of identified defense counsel. This is corroborated by the fact that the defendants were found in default, leading to a judgment on the merits and a permanent injunction in favor of the plaintiffs. The lack of legal representation for the defendants is noted as a significant procedural detail that likely contributed to the accelerated timeline and the outcome of the case.

In a related International Trade Commission (ITC) investigation (337-TA-1417) concerning similar hydrodermabrasion systems, MIRAmedtech UG and MIRAmedtech SP. Z.O.O. were also found in default, further suggesting a pattern of non-appearance by the defendants in these legal proceedings.